Attached files
| file | filename |
|---|---|
| EX-99.2 - WaferGen Bio-systems, Inc. | ex_99-2.htm |
| EX-99.1 - WaferGen Bio-systems, Inc. | ex_99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 18, 2014
|
WaferGen Bio-systems, Inc.
|
||
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
000-53252
|
90-0416683
|
||||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
7400 Paseo Padre Parkway, Fremont, CA
|
94555
|
|||
|
(Address of principal executive offices)
|
(Zip Code)
|
(Registrant’s telephone number, including area code): (510) 651-4450
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Information.
On March 24, 2014, WaferGen Bio-systems, Inc. (the “Company”) held a conference call and live audio webcast to discuss its financial results for the quarter and year ended December 31, 2013.
A copy of the press release announcing the call is being furnished as Exhibit 99.1 to this Report on Form 8-K. A transcript of the call is being furnished as Exhibit 99.2 to this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
9.01. Financial Statements and Exhibits.
Exhibits
The exhibits required to be filed as a part of this Current Report on Form 8-K are listed in the Exhibit Index attached hereto and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
WaferGen Bio-systems, Inc.
|
|||
|
Date: March 24, 2014
|
By:
|
/s/ IVAN TRIFUNOVICH | |
|
Ivan Trifunovich
|
|||
|
President and Chief Executive Officer
|
|||
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release, dated March 18, 2014, furnished herewith
|
|
|
99.2
|
Transcript for conference call held March 24, 2014, furnished herewith
|